Subcutaneous Efgartigimod Expands Payer Potential For Argenx’s Drug
Offers gMG Patients Freedom From I.V. Treatment
With positive Phase III data for the injectable version of its myasthenia gravis therapy, the company expects most patients to use it over intravenous Vyvgart, opening more avenues for reimbursement.
You may also be interested in...
Public Company Edition: An IPO and three big follow-on offerings hit the market but other public companies revealed plans to cut costs or reprioritize their R&D pipelines, signaling that uncertainty remains.
Tim Van Hauwermeiren, CEO of Argenx, has been on the road with the firm's field force for the US launch of Vyvgart for generalized myasthenia gravis and has been enthused by the positive response from physicians.
Despite a US approval for its novel FcRn inhibitor Vyvgart in gMG, the firm has realistic expectations of sales, factoring in concerns about COVID-19 and lagging medical education.